CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

CRISPR Therapeutics AG (CRSP) declined 3.45% to $51.55, underperforming the S&P 500's 0.06% loss. Despite a 3.23% monthly gain, the stock faces headwinds. The company is expected to report an EPS of -$1.06 but projects significant revenue growth of 971.24% year-over-year. CRSP holds a Zacks Rank #2 (Buy) rating, though its industry ranks in the bottom 33% of all sectors.